OncoMatch/Hodgkin Lymphoma (HL)/PD-L1 (CD274)

Hodgkin Lymphoma (HL)PD-L1 (CD274) Clinical Trials

Classical Hodgkin lymphoma (cHL) has among the highest PD-L1 expression of any cancer, driven by 9p24.1 amplification of PD-L1/PD-L2, making it exquisitely sensitive to PD-1 checkpoint inhibition. Pembrolizumab and nivolumab are FDA-approved for relapsed/refractory cHL after brentuximab vedotin and ≥2 prior lines. Trials investigate PD-1 inhibitors in frontline combinations (replacing ABVD components), post-transplant maintenance, and nivolumab plus brentuximab vedotin as chemotherapy-free regimens.